摘要
目的通过不同批次何首乌样品细胞毒性的差异,探究其潜在肝损伤成分。方法采用超高效液相色谱-三重四极杆质谱法(UPLC-QQQ-MS/MS)对何首乌成分进行定量检测,运用聚类分析法(Hierarchical Cluster Analysis,HCA)对22批何首乌样品进行聚类;以HepaRG细胞半数抑制浓度(Half Inhibitory Concentration,IC50)为指标,对不同类别何首乌样品进行毒性评价,获取不同组别毒性差异。随后,通过正交偏最小二乘-判别分析(Orthogonal Partial Least Squares Discriminant Analysis,OPLS-DA)揭示肝细胞毒性作用与何首乌物质基础的相关性,筛选毒性差异成分。结果22批样品可依据共有化合物分为A、B、C 3组。HepaRG细胞结果表明,3组间毒性作用B组1的潜在毒性成分。结论不同组别何首乌样品,存在毒性差异,其中2,3,5,4'-四羟基二苯乙烯-2-O-β-D-葡萄糖苷、大黄素-8-O-β-D-葡萄糖苷、儿茶素可能为潜在毒性成分。
Objective To explore potential hepatotoxic components based on the differences in cytotoxicity between different batches of Polygoni Multiflori Radix(PM).Methods Ultra-performance liquid chromatography-triple quadrupole mass spectrometry(UPLC-QQQ-MS/MS)was used for quantitative detection of PM while hierarchical cluster analysis was used to classify samples.The half inhibitory concentration(IC50)of HepaRG cells was used as the index to evaluate the toxicity of categorized samples and to reveal the differences between different groups.Orthogonal partial least squares discriminant analysis was used to identify the differences in toxicity between different groups and screen for differential components.Results Twenty-two batches of samples were divided into categories A,B,and C based on common compounds.The IC50 of HepaRG cells indicated that the three groups of samples were significantly different in terms of toxicity,which was the highest in group B,followed by group A and group C.The results of OPLS-DA suggested that the discrimination rate of the models between groups A,B,and C was good,and three potential toxic components with VIP>1 were obtained.Conclusion Different categories of PM samples exhibit differences in toxicity.trans-2,3,5,4’-tetrahydroxystilbene-2-O-β-D-glucoside(THSG),emodin-8-O-β-D-glucoside(EG)and catechin are potential toxic components of PM.
作者
李妍怡
文海若
杨颜榕
马双成
汪祺
LI Yanyi;WEN Hairuo;YANG Yanrong;MA Shuangcheng;WANG Qi(School of Chinese Materia Medica,Beijing University of Chinese Medicine,Beijing 102400,China;National Center for Safety Evaluation of Drugs,National Institutes for Food and Drug Control,Beijing 100176,China;Shenyang Pharmaceutical University,School of Functional Food and Wine,Shenyang Liaoning 110016,China;Chinese Pharmacopoeia Commission,Beijing 100061,China;State Key Laboratorg of Drug Regulactorg Science,Beijing 100061,China;Institute of Chinese Traditional Medicine and Ethnic Medicine,National Institutes for Food and Drug Control,Beijing 100050,China)
出处
《中国药物警戒》
2024年第12期1377-1381,共5页
Chinese Journal of Pharmacovigilance
基金
国家自然科学基金资助项目(82374033)。
